Teladoc Health (NYSE: TDOC) announced its 2021 Q3 financial results on October 27, 2021.
According to the announcement, total revenue was up 108% (9 months, YoY). Among them, subscription-based Access Fees revenue was up 133%. In addition, the other revenues, including that for chronic care, were up 177%.
On the other hand, Teladoc recorded up 368% and 358% of loss from operation and net loss, respectively (9 months, YoY). Among 224 million USD loss from operation in 9 months, depreciation & amortization account for 152 million USD, and acquisition, integration and transformation costs account for 22 million USD. In addition to these acquisition related costs, Teladoc recorded 239 million USD of technology development, which was up 231% (YoY).
These figures show that Teladoc is making aggressive upfront investments. Especially, Business performance of the new business acquired from Livongo and InTouch Health also seems improving.
Despite its net loss, Teladoc continuously recorded positive free cash flow in 2021 Q3. Adjusted EBITDA was up 149% (9 months, YoY).
According to the recent announcement, Teladoc ranked 1st in consumer satisfaction by J.D. Power 2021 U.S. Telehealth Satisfaction Study, showing strong supports by customers. Watanabe & Brothers’ Investment expects acceleration of Teladoc’s growth in near future.
- Watanabe & Brothers’ Investment is holding shares of Teladoc Health.
- This report is provided solely for informational purpose and not intended for the purpose of soliciting investment in, or as a recommendation to purchase or sell any specific products.
- Any opinions or statements expressed in this report are based on the author’s personal and subjective views, and are not the official views of the organization to which the author belongs. In addition, although we have done our best efforts in making accurate assessments on the original financial statements, we cannot guarantee any complete accuracy of this report. We do not guarantee either that any future forecasts referred to in this report will certainly be realized. Investment in listed stocks, ETFs, etc. should be carried out under the responsibility of each investor, and even if the investor who read this report suffers a loss due to investment activities, Watanabe & Brothers’ Investment is not responsible for any liability.
- This report was originally prepared in English, and translated into the other languages with plugin utilizing Google Translation API. We hereby notify that the translations are provided only for the sake of reference, and any opinions or statements in this report should be interpreted in original English. We ask any investors reading this report to refer to the original financial statements issued by the company.